Edwards Lifesciences Corporation (EW) financial statements and ratios from SEC XBRL: revenue $6.07B (TTM), net margin 17.7%, revenue growth 11.5% YoY, P/E 40.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.07B |
| Net Margin | 17.7% |
| Revenue Growth (YoY) | 11.5% |
| EPS Growth (YoY) | -73.6% |
| FCF Growth (YoY) | 360.5% |
| P/E Ratio | 40.0 |
| EV / EBITDA | 24.1 |
| Price / Book | 4.83 |
| Price / Sales | 7.86 |
| FCF Yield | 2.9% |
| DCF Value (model) | $30.60 |
| DCF Upside vs Price | -65.9% |
| Altman Z-Score | 11.95 (safe) |
| Piotroski F-Score | 6/9 |
| Sector P/E (Healthcare) | 21.6 |
EW overview · EW earnings · EW KPIs · EW investor relations · EW ownership · EW peers · EW filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.